Journal of Neuro-Oncology最新文献

{"title":"One-year follow-up of the new European reference network for pediatric cancers (ERN PaedCan) tumor board for pediatric CNS tumors: lessons learnt and future prospects.","authors":"Marthe Sönksen, Brigitte Bison, Lisa Bußenius, Jelena Rascon, Denise Obrecht-Sturm, Barry Pizer, Katrin Scheinemann, Martin Schalling, Ruth Ladenstein, Martin Mynarek, Stefan Rutkowski","doi":"10.1007/s11060-025-05189-5","DOIUrl":"10.1007/s11060-025-05189-5","url":null,"abstract":"<p><strong>Purpose: </strong>European Reference Networks (ERN) are collaborative networks connecting healthcare professionals across Europe. A virtual multidisciplinary tumor board (VMTB) for children with central nervous system (CNS) tumors was established within the ERN for pediatric oncology (ERN PaedCan) in 2022. We report the experience with this new format.</p><p><strong>Methods: </strong>A web-based questionnaire was distributed to physicians for cases presented between November 2022 and November 2023, addressing the implementation of provided recommendations, satisfaction and basic data about the local institution. Baseline information of the presented cases was taken from anonymized VMTB protocols.</p><p><strong>Results: </strong>In the first year, 19 patients from 11 institutions located in nine European countries were discussed in 21 VMTB. The German national reference center for neuroradiology demonstrated MRI findings in 19/21 (91%) conferences. 19 questionnaires were answered by physicians from all participating countries. Main reason for VMTB presentation were questions about therapy (79%). Presenting institutions treated a median of 10 (5-150) neuro-oncological pediatric patients per year. All hospitals conducted own institutional tumor boards. National central review was available in 3/9 countries (33%). Recommendations were followed, at least partly, in all except one patient experiencing unexpected clinical deterioration. Recommendations were considered helpful in 90%. All participants would recommend the VMTB to colleagues. Technical issues regarding data provision were reported as the main obstacle in 56%.</p><p><strong>Conclusion: </strong>A European VMTB for pediatric patients with CNS tumors is feasible and perceived as useful by the participants. Recommendations were followed frequently. Optimization of privacy-compliant data exchange is crucial for continuance of the format.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1415-1423"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic antitumor and radiosensitizing effects of α-sulfoquinovosyl-acylpropanediol (SQAP) via PI3K/Akt inhibition and DNA repair impairment in glioblastoma.","authors":"Takayuki Nishiwaki, Urara Kudo, Shinsuke Nakamura, Yoshiki Kuse, Yoshiaki Harakawa, Fukka You, Kenji Shoda, Tetsuya Yamada, Hiroaki Takei, Yusuke Egashira, Hideaki Hara, Noriyuki Nakayama, Tsuyoshi Izumo, Masamitsu Shimazawa","doi":"10.1007/s11060-025-05194-8","DOIUrl":"10.1007/s11060-025-05194-8","url":null,"abstract":"<p><strong>Purpose: </strong>Radiotherapy remains a key treatment modality for glioblastoma (GBM), but therapeutic resistance and radiation-induced toxicity severely limit its efficacy. Therefore, the development of novel, safe, and effective radiosensitizers is urgently needed. α-Sulfoquinovosylacylpropandiol (SQAP), a marine-derived compound, has demonstrated potent radiosensitizing effects in cancer cells by improving tumor oxygenation and interfering with DNA repair. However, its impact on GBM has not yet been investigated. This study aimed to evaluate the biological effects of SQAP on GBM cells and assess its potential as a radiosensitizer for future clinical application.</p><p><strong>Methods: </strong>In vitro analyses-including cell viability, colony formation, immunoblotting, quantitative reverse transcription polymerase chain reaction, immunocytochemistry, and cell death/proliferation assays-were conducted to examine SQAP's mechanisms of action. In vivo efficacy and safety were evaluated using a murine intracranial glioma model.</p><p><strong>Results: </strong>SQAP inhibited GBM cell proliferation while sparing normal astrocytes. In combination with radiotherapy, SQAP significantly reduced colony formation and enhanced cell death without affecting mitosis. SQAP decreased PI3K/Akt phosphorylation and modulated the expression of downstream apoptotic and cell cycle-related proteins. Additionally, SQAP suppressed HIF-1α and VEGF expression. Although SQAP alone did not cause DNA damage, it delayed radiotherapy-induced DNA repair, as shown by prolonged γH2AX expression and reduced 53BP1 nuclear expression.</p><p><strong>Conclusion: </strong>SQAP exerts both antitumor and radiosensitizing effects in GBM models by inhibiting PI3K/Akt signaling, suppressing hypoxia-related pathways, and impairing DNA repair. These findings support its potential as a promising adjunctive agent in GBM therapy.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1131-1146"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry.","authors":"Cassia Bree Trewin-Nybråten, Paul Christopher Lambert, Kirsten Marienhagen, Lasse Andreassen, Tom Børge Johannesen, Pitt Niehusmann, Leif Oltedal, Stephanie Schipmann, Anne Jarstein Skjulsvik, Ole Solheim, Tora Skeidsvoll Solheim, Terje Sundstrøm, Einar Osland Vik-Mo, Petter Brandal, Tor Ingebrigtsen, Erlend Skaga","doi":"10.1007/s11060-025-05218-3","DOIUrl":"10.1007/s11060-025-05218-3","url":null,"abstract":"<p><strong>Purpose: </strong>Surveillance of patient outcomes with real-world data is essential to uncover regional disparities in clinical practice or quality of care. This study explored survival differences among glioblastoma patients in Norway and investigated the role of demographic and treatment factors.</p><p><strong>Methods: </strong>We analyzed real-world data from the Norwegian Cancer Registry on 1158 adults with histologically confirmed glioblastoma during 2019-2023. Surgical treatment rates per 100,000 inhabitants per region (South-East, West, Mid, North) were compared using adjusted Poisson models. Full treatment included surgical resection, radiotherapy (≥ 55 Gy for ≤ 70 years; ≥30 Gy for > 70 years), and temozolomide. Standardized survival was estimated with flexible parametric models, standardized for age, sex, year, and distances to treatment facilities.</p><p><strong>Results: </strong>Patients from the North were older and lived further from treatment centers. For patients aged 18-70, treatment and survival did not significantly differ across regions; national median standardized survival was 14.4 months (95%CI:13.6-15.2). For elderly patients (71-89 years), the North demonstrated a higher surgical treatment rate (rate ratio = 1.32; 95%CI = 0.99-1.77), but lesser use of postoperative radiotherapy and temozolomide. Median standardized survival for elderly patients in the North was 4.5 months (95%CI: 3.5-5.7) versus 7.7 (6.9-8.6) months nationally. Early mortality was particularly high for elderly patients in the North, yet those surviving beyond six months matched other regions' survival probability.</p><p><strong>Conclusion: </strong>Lower glioblastoma survival in the North was associated with higher early mortality among elderly patients, likely due to selecting frailer patients for surgery, who less often subsequently received anti-neoplastic treatment.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1355-1366"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic radiosurgery for brain metastases: evolving practice patterns from the national cancer database (2004-2020).","authors":"Jonathan J Shih, Bhav Jain, Rohan Patel, Urvish Jain, Miranda Lam, Fumiko Chino, Manali I Patel, Edward Christopher Dee, Erqi Pollom, Gordon Li, Kekoa Taparra","doi":"10.1007/s11060-025-05178-8","DOIUrl":"10.1007/s11060-025-05178-8","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1211-1225"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144957672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of substructure radiation dose on health-related quality of life in children with brain tumors: a Pediatric Proton/Photon Consortium Registry (PPCR) study.","authors":"Mikaela Doig, Jae Lee, Young Kwok, Iain MacEwan, Suzanne Wolden, Keith Allison, Sara Dennehy, Benjamin Bajaj, Michala Short, Peter Gorayski, Eva Bezak, Torunn I Yock","doi":"10.1007/s11060-025-05211-w","DOIUrl":"10.1007/s11060-025-05211-w","url":null,"abstract":"<p><strong>Purpose: </strong>Cranial irradiation is associated with health-related quality of life (HRQoL) deficits in childhood cancer survivors. We investigated the relationship between radiation dose to brain substructures and HRQoL in children with brain tumors treated with proton beam therapy (PBT).</p><p><strong>Methods: </strong>Data were obtained from children in the Pediatric Proton/Photon Consortium Registry who received PBT for primary brain tumors between 2015 and 2021. HRQoL was assessed using PedsQL Generic Core questionnaires during the first week of PBT and annually thereafter. Standardized substructure segmentations and dosimetry data were correlated with parent-proxy reported HRQoL scores using Pearson correlations.</p><p><strong>Results: </strong>Seventy-six patients were included, with median age 8.9 years (range 1.2-16.5) at diagnosis. Median follow-up was 5.0 years post-PBT and median prescribed dose was 54Gy_RBE. HRQoL scores were lower than normative population values during PBT, particularly in those who received craniospinal irradiation (CSI) (p < 0.05). Across the total cohort, higher mean doses to the whole brain, supratentorial brain, corpus callosum, left hippocampus, hypothalamus, optic chiasm, pituitary and thalamus correlated with worse HRQoL (r= -0.24 to -0.39), p < 0.05). In the CSI subgroup (n = 17), moderate-to-strong associations between dose to these structures and physical functioning (r= -0.50 to -0.79, p < 0.05) were observed. In children who received focal PBT (n = 59), weaker associations were observed between dose to the hypothalamus and pituitary, and HRQoL (r = -0.28 to -0.36, p < 0.05).</p><p><strong>Conclusion: </strong>Higher radiation doses to specific brain substructures were associated with poorer HRQoL outcomes after PBT. Minimizing dose to these areas during treatment planning may help preserve HRQoL in survivors.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1443-1453"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of modern radiation therapy for pituitary adenoma - different techniques: single institute experience.","authors":"Alexandra Brand, Linda Agolli, Kerem Tuna Tas, Phillip Lishwiski, Markus Schymalla, Klemens Zink, Hilke Vorwerk, Ioanna Fragkandrea-Nixon, Thomas Held, Daniel Habermehl, Sebastian Adeberg, Ahmed Gawish","doi":"10.1007/s11060-025-05228-1","DOIUrl":"10.1007/s11060-025-05228-1","url":null,"abstract":"<p><strong>Background: </strong>Pituitary adenomas are relatively common benign intracranial tumors that may cause significant hormonal imbalances and visual impairments. Radiotherapy (RT) remains an important treatment option, particularly for patients with residual tumor after surgery, recurrent disease, or ongoing hormonal hypersecretion. This study summarizes long-term clinical outcomes and radiation-associated toxicities in patients with pituitary adenomas treated with contemporary radiotherapy techniques at a single institution.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 122 patients treated with RT for pituitary adenomas at the tertiary Hospital in Germany between 1992 and 2023. Patient data were assessed for tumor characteristics, treatment modalities, and outcomes. Overall survival (OS), and local control (LC) were evaluated using Kaplan-Meier analysis. Statistical comparisons between subgroups were performed with the log-rank test. Treatment-related toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.</p><p><strong>Results: </strong>Median follow-up was 107 months from initial diagnosis and 63 months post-RT. Most patients (96%) received fractionated stereotactic radiotherapy (FSRT), and 4% underwent single-session radiosurgery. RT achieved LC rates of 95% and 75% at 5 and 20 years, respectively. Proton therapy significantly improved LC and overall survival (OS) compared to photon-based treatments (p < 0.01). Hypopituitarism was the most common long-term toxicity, occurring in 40% of patients, while visual impairments were rare (< 3%). Tumor recurrence occurred in 9% of patients, primarily in those treated with delayed RT after incomplete resection.</p><p><strong>Conclusion: </strong>Modern RT techniques, particularly proton therapy, provide durable tumor control and manageable toxicity profiles for pituitary adenomas. Optimized timing and precision in RT delivery are critical to enhancing outcomes and minimizing complications. Long-term follow-up remains essential to monitor disease progression and late toxicities.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1039-1050"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intra-cavitary radiotherapy for surgically resected brain metastases: a comprehensive analysis including an individual patient data meta-analysis of intraoperative radiotherapy (IORT) and brachytherapy (IBT).","authors":"Alexandru Guranda, Erdem Güresir, Arne Mathias Ruder, Frank Anton Giordano, Johannes Wach","doi":"10.1007/s11060-025-05227-2","DOIUrl":"10.1007/s11060-025-05227-2","url":null,"abstract":"<p><strong>Background: </strong>Surgical resection followed by adjuvant radiotherapy is a standard approach for brain metastases (BM). Intracavitary radiotherapy techniques-namely intraoperative radiotherapy (IORT) and brachytherapy (IBT)-have gained attention as alternatives to stereotactic radiotherapy, potentially reducing neurotoxicity and treatment delays. However, robust comparative data remain scarce.</p><p><strong>Methods: </strong>We performed a systematic meta-analysis including both conventional and reconstructed individual patient data (IPD) from studies reporting outcomes after intracavitary radiotherapy post-BM resection. Primary endpoint was local control rate (LCR); secondary endpoints included overall survival (OS), distant brain control (DBC), radiation necrosis (RN), and leptomeningeal disease (LMD). IPD was reconstructed from published Kaplan-Meier curves. Survival and incidence outcomes were pooled using random-effects models in R.</p><p><strong>Results: </strong>Twenty-three studies with 858 patients were analyzed. The 1-year LCR was 96% (95% CI: 94-98%) for IORT and 95% (95% CI: 92-97%) for IBT. Median OS in patients who underwent IORT was 39.1 months (95% CI: 22.0-59.5), and 15.9 months (95% CI: 12.6-19.9) in whose who underwent IBT, respectively (p = 0.004; HR 0.64). IORT was associated with lower RN (4% vs. 7%) and LMD (6% vs. 9%). The 1-year DBC rate was higher for IORT (57%) than IBT (48%).</p><p><strong>Conclusions: </strong>Intracavitary radiotherapy yields excellent local control after BM resection. This IPD meta-analysis provides the most comprehensive evidence to date and supports further prospective evaluation of IORT in neuro-oncological care.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"907-919"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor and immune cell distribution in the tumor core and outer part of glioblastoma, IDH wildtype.","authors":"Vilde Pedersen, Arnon Møldrup Knudsen, Signe Regner Michaelsen, Rikke Hedegaard Dahlrot, Bjarne Winther Kristensen","doi":"10.1007/s11060-025-05232-5","DOIUrl":"10.1007/s11060-025-05232-5","url":null,"abstract":"<p><strong>Purpose: </strong>Glioblastoma, IDH-wildtype is the most frequent and malignant primary brain tumor in adults. Tumor cells infiltrate the brain parenchyma, preventing complete resection and causing progression. Immune therapies have limited effect, but little is known about the frequency and type of immune cells in the outer part of glioblastoma, IDH-wildtype, where tumor cells start to infiltrate the brain (transition zone) and diffusely infiltrate the brain parenchyma (tumor periphery). We aimed to quantify the type and distribution of immune cells in glioblastomas, IDH-wildtype covering these areas.</p><p><strong>Methods: </strong>We established a cohort of 54 glioblastomas, IDH-wildtype containing tissue from the tumor core, transition zone, and periphery. Patients were included if most tumor cells were positive in immunohistochemical staining for P53. Tissue sections were subject to multiplex immunohistochemistry and stained with P53 (tumor), FOXP3 (regulatory T cells), CD8 (cytotoxic T cells), and IBA1 (microglia/macrophages). A software-based classifier was trained to count the cells.</p><p><strong>Results: </strong>The densities of CD8+, FOXP3+, and IBA1+ cells were significantly higher in the core than in the periphery and in the transition zone than in the periphery. However, the CD8+, FOXP3+, and IBA1+ cell/tumor cell ratio increased from the core to the transition zone, and the CD8+ and IBA1+ cell/tumor cell ratio increased again to the periphery. The core had the highest FOXP3+/CD8+ ratio, as well as the highest fraction of tumor cells with IBA1+ cells, CD8+ cells, and FOXP3+ cells in proximity.</p><p><strong>Conclusion: </strong>This study highlights spatial differences in the immune microenvironment with potential implications for future immune-therapeutic strategies.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1187-1198"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repeat stereotactic radiosurgery for treatment of brain metastases locally recurrent following initial radiosurgery.","authors":"Jennifer C Hall, Keshav Goel, Yulia Lozko, Steven D Chang, David J Park, Yusuke S Hori, Fred C Lam, Deyaldeen AbuReesh, Scott Jackson, Gordon Li, Melanie Hayden-Gephart, Taryn Kaneko, Seema Nagpal, Iris C Gibbs, Elham Rahimy, John Byun, Katherine Jin, Erqi Pollom, Scott G Soltys","doi":"10.1007/s11060-025-05201-y","DOIUrl":"10.1007/s11060-025-05201-y","url":null,"abstract":"<p><strong>Purpose: </strong>We report outcomes of repeat stereotactic radiosurgery (rSRS) to sites of tumor progression following initial SRS. Additionally, we sought to determine if, at the time of recurrence following initial SRS, surgical resection of the tumor followed by SRS (surgery + rSRS) provided benefit compared to rSRS alone.</p><p><strong>Methods: </strong>We retrospectively reviewed patients treated with rSRS for local recurrence after initial SRS. The cumulative incidences of LF and adverse radiation effect (ARE), with death as a competing risk, were estimated.</p><p><strong>Results: </strong>From 2004 to 2022, we identified 77 patients with 429 brain metastases treated with initial SRS, of which 97 metastases were treated with rSRS for salvage of LF following initial SRS; 49 metastases had resection prior to rSRS. Of the 429 brain metastases treated with initial SRS, the cumulative incidence of LF was 12.6% [95% confidence interval (CI) 9.7-15.9] at 1 year; in 97 sites treated with rSRS, LF was 14.6% (95%CI 8.4-22.4) at 1 year. There was no significant difference (p = 0.3) in 1-year LF after surgery + rSRS [11.1% (95%CI 4.0-22.31)] versus rSRS alone [18.4% (95%CI 9.0-30.5)]. The 1-year rates of ARE were: 3.0% (95%CI 1.7-5.0%) for initial SRS (overall grade 1-4), 15.6% (95%CI 9.2-23.6) for rSRS (overall grade 1-4), and 12.6% (95%CI 6.8-20.1%) for rSRS (symptomatic grade 2-4).</p><p><strong>Conclusion: </strong>Given that the 1-year local progression of 15% with rSRS is similar to the 13% of initial SRS, our data do not support that tumors recurrent after initial SRS are inherently radioresistant to salvage SRS. Tumor control must be balanced by the 1-year rates of adverse radiation effect (16% overall, 13% symptomatic).</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1271-1283"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical-pathological patterns and prognosis of young women with breast cancer brain metastases: a single-center retrospective study.","authors":"Isabella Kojundzic, Jamie Lee Fritz, Badr Id Said, Sandy Vuong, Hany Soliman, Marguerite Ennis, Ellen Warner, Katarzyna Joanna Jerzak","doi":"10.1007/s11060-025-05212-9","DOIUrl":"10.1007/s11060-025-05212-9","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.</p><p><strong>Methods: </strong>In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018. Young women were defined as those who were < 40 years of age at the time of diagnosis of CNS metastases. Descriptive statistics were completed, and survival analyses performed.</p><p><strong>Results: </strong>Similar clinical and pathological characteristics were observed among young and older women with CNS metastases. However, young women were significantly more likely to develop leptomeningeal metastatic disease (LMD) than older women (39.6% vs. 22.3%, p = 0.004). Additionally, young women were significantly more likely to be re-treated for CNS metastases (43.4% vs. 24.5%, p = 0.003). There was no significant difference in median brain-specific progression-free survival (bs-PFS) (log-rank p = 0.35) or overall survival (OS) (log-rank p value = 0.52) between young and older women.</p><p><strong>Conclusions: </strong>Women < 40 years of age were more likely to develop LMD than women ≥ 40 years of age. Although young women were also more likely to be re-treated for progression of CNS metastases, their bs-PFS and OS were not inferior to those ≥ 40 years of age.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"993-1000"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}